Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00294671 · ClinicalTrials.gov registry record · Phase 2

The Effect of Diflunisal on Familial Amyloidosis

A Phase 2 study of Familial Amyloid Polyneuropathy and Familial Amyloidosis, sponsored by Boston University.

Completed
Registry status
Phase 2
Development phase
130
Enrollment target
8
Study locations

NCT00294671 is a Phase 2 study of Familial Amyloid Polyneuropathy and Familial Amyloidosis that has completed, run by Boston University. The registered enrollment target is 130 participants. The trial reports 8 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00294671, a Phase 2 study of Familial Amyloid Polyneuropathy and Familial Amyloidosis, has completed, sponsored by Boston University.

COMPLETED
Registry status
Phase 2
Development phase
130 participants
Enrollment target
8
Study locations

Study Summary

The purpose of this study is to determine if diflunisal can prevent progressive lower leg nerve damage in patients with familial amyloidosis polyneuropathy. Funding Source - FDA Office of Orphan Products Development (OOPD); National Institute of Neurological Disorders and Stroke (NINDS)

Interventions

  • OTHER placebo
  • DRUG diflunisal

Study Locations (8)

Other

  • IRCCS Policlinico San Matteo - Pavia
  • Kumamoto University - Kumamoto
  • Shinshu University - Matsumoto
  • Umea University Hospital - Umeå
  • King's College Hospital - London

Massachusetts

  • Amyloidosis Center, Boston Medical Center - Boston

Minnesota

  • Mayo Clinic Rochester - Rochester

New York

  • Mount Sinai School of Medicine, Department of Medicine - New York

Trial Details

FieldValue
Enrollment Target 130 participants
Start Date 2006-02
Est. Completion 2012-12
Phase Phase 2

Sponsor

Boston University

185 total trials

What the Registry Record Tells You About NCT00294671

The ClinicalTrials.gov registry entry for NCT00294671 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 130 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston University, which has 185 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Familial Amyloid Polyneuropathy appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.

NCT00294671 reports 8 study locations spanning 4 distinct geographic areas - top geographies include Other, Massachusetts, Minnesota.

Frequently Asked Questions

What is clinical trial NCT00294671 about?

NCT00294671 is a clinical study titled "The Effect of Diflunisal on Familial Amyloidosis". The purpose of this study is to determine if diflunisal can prevent progressive lower leg nerve damage in patients with familial amyloidosis polyneuropathy. Funding Source - FDA Office of Orphan Products Development (OOPD); National Institute of Neurological Disorders and Stroke (NINDS)

What is the current status of trial NCT00294671?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 130 participants. The study started on 2006-02. Estimated completion is 2012-12.

What conditions does trial NCT00294671 study?

This clinical trial studies the following conditions: Familial Amyloid Polyneuropathy, Familial Amyloidosis.

What interventions are being tested in trial NCT00294671?

The interventions under investigation include: placebo (OTHER), diflunisal (DRUG).

Who is sponsoring clinical trial NCT00294671?

This trial is sponsored by Boston University, which has 185 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00294671 being conducted?

This trial has 8 study locations across Massachusetts, Minnesota, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.